ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

INO Inovio Pharmaceuticals Inc New

11.77
-0.33 (-2.73%)
Last Updated: 20:36:15
Delayed by 15 minutes
Share Name Share Symbol Market Type
Inovio Pharmaceuticals Inc New NASDAQ:INO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.33 -2.73% 11.77 11.76 11.83 12.355 11.69 12.31 231,639 20:36:15

May 2020 Deadline Approaching for Inovio Pharmaceuticals (INO) Class Action

05/05/2020 9:16pm

PR Newswire (US)


Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Inovio Pharmaceuticals Charts.

CHESTNUT HILL, Mass., May 5, 2020 /PRNewswire/ -- Sokolove Law announces an investigation into a securities class action lawsuit filed against Inovio Pharmaceuticals (NASDAQ: INO) on behalf of shareholders. INO investors that purchased 20,000 shares or more between February 14 to March 9, 2020 and are interested in learning more about the class action lawsuit should call 800-974-3478 to explore their legal rights. The May 12th deadline is approaching, time is extremely limited- shareholders are encouraged to call without delay.

For more information visit: INOFraud.com

The lawsuit alleges that between February 14, 2020 and March 9, 2020 the defendants capitalized on extreme COVID-19 panic by falsely claiming that Inovio Pharmaceuticals, Inc. had developed a vaccine for COVID-19. The lawsuit also alleges that Inovio Pharmaceuticals CEO J. Joseph Kim appeared on Fox Business News and stated Inovio had developed a COVID-19 vaccine. After J. Joseph Kim's statement, the market responded favorably and Inovio's stock price quadrupled from $4.28 a share on February 28, 2020, and continued to rise in subsequent weeks, reaching an intra-day high of $19.36 on March 9, 2020. It is alleged that Inovio had not developed a COVID-19 vaccine. The lawsuit states that on March 9, 2020, before trading commenced, Citron Research exposed the misstatements, calling for an SEC investigation into the matter. In response, Inovio's stock price fell dramatically from its March 9 opening price of $18.72 per share to close to $9.83. The following day, March 10, 2020, Inovio's stock price fell from its $9.30 per share opening price to close at $5.70 per share.

If you are an INO investor who purchased 20,000 shares or more between February 14, 2020 to March 9, 2020, call our experienced case managers now at 800-974-3478 to discuss your legal rights in this securities fraud class action lawsuit.

The class has not been certified yet. You are not represented by an attorney until certification occurs. If you do not take action you can remain an absent class member. There is no required minimum number of shares to be a class member.

About Sokolove Law

Sokolove Law provides quality legal services that help people obtain access to the civil justice system. For more than 40 years, Sokolove Law has worked to educate people about their legal rights and helped thousands of injured parties obtain the compensation they deserved from their legal claims. Sokolove Law is a national law firm with offices and a licensed attorney in nearly every state. The firm operates as a limited liability company in all states except Virginia, California, Michigan and Tennessee, where it operates as a limited liability partnership. For more information on Sokolove Law, please visit www.sokolovelawfirm.com

THIS IS AN ADVERTISEMENT Sokolove Law, LLC, 1330 Boylston St, Suite 400, Chestnut Hill, MA 02467. Ricky LeBlanc admitted in MA only. While this firm maintains joint responsibility, most cases of this type are referred to other attorneys for principal responsibility. This is general information only and should not be taken or relied on as legal, medical, or other advice. No attorney-client or other professional relationship is created by providing or using this information. Prior results do not guarantee a similar outcome. ©2020 Sokolove Law, LLC

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/may-2020-deadline-approaching-for-inovio-pharmaceuticals-ino-class-action-301053210.html

SOURCE Sokolove Law, LLC

Copyright 2020 PR Newswire

1 Year Inovio Pharmaceuticals Chart

1 Year Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock